Efficacy of Onapristone in PR-Expressing Tumors

July 14, 2015
Alexander Zukiwski, MD

Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.

ONA was previously evaluated in women with breast cancer, and it produced positive results. Zukiwski and his team reevaluated the drug in a phase I study, believing that they solved one of its major safety issues. They recently started a phase II study in women who have recurrent and metastatic endometrial cancer.

Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.